FDA calendar · December 2021 · built from SEC filings

PDUFA dates December 2021: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in December 2021. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in December 2021

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

December 2021: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Dec 2021Month disclosedZYNRELEF® (bupivacaine-meloxicam)HRTXFDA approval—ApprovedSEC 8-K Exhibit 99.1
December 3, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 7, 2021Clindamycin Phosphate In 0.9% Sodium Chloride (clindamycin phosphate)OGNFDA approval—ApprovedopenFDA Drugs@FDA
December 9, 2021Zepatier (elbasvir; grazoprevir)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 10, 2021Lastacaft (alcaftadine)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
December 10, 2021Epzicom (abacavir sulfate; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 10, 2021Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
December 10, 2021KISQALI® (ribociclib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
December 14, 2021RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
December 14, 2021Xeljanz (tofacitinib citrate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
December 15, 2021Orencia (abatacept)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
December 15, 2021YCANTH (cantharidin)VRCANDA/BLA accepted—Completedsec_424b
December 17, 2021Vyvgart (efgartigimod alfa)ARGXFDA approval—ApprovedopenFDA Drugs@FDA
December 17, 2021Tezspire (tezepelumab-ekko)AZNFDA approval—ApprovedopenFDA Drugs@FDA
December 17, 2021Caplyta (lumateperone tosylate)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
December 17, 2021Rezvoglar (insulin glargine-aglr)LLYFDA approval—ApprovedopenFDA Drugs@FDA
December 17, 2021Rezvoglar (insulin glargine-aglr)LLYComplete Response Letter—CRL issuedFDA Complete Response Letters
December 17, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 17, 2021Eohilia (budesonide)TAKComplete Response Letter—CRL issuedFDA Complete Response Letters
December 17, 2021Gozellix (gallium ga-68 gozetotide)TLXFDA approval—ApprovedopenFDA Drugs@FDA
December 20, 2021Otezla (apremilast)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
December 20, 2021Vocabria (cabotegravir sodium)GSKFDA approval—ApprovedopenFDA Drugs@FDA
December 20, 2021Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
December 20, 2021Xarelto (rivaroxaban)JNJFDA approval—ApprovedopenFDA Drugs@FDA
December 22, 2021Leqvio (inclisiran sodium)NVSFDA approval—ApprovedopenFDA Drugs@FDA
December 22, 2021Cosentyx (secukinumab)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
December 30, 2021Afinitor (everolimus)NVSLabel expansion—ApprovedopenFDA Drugs@FDA

December 2021: dated readouts

No events in this view.

Questions

What PDUFA dates are in December 2021?

0 PDUFA dates fell in December 2021. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.